Solicitations

0
Awards
0
Total Funding Awarded
0
Estimated Value of Projects
How Does This Work?

JPM-MCS, and other customers (DTRA/JSTO, etc.), offers funding opportunities to MCDC members through solicitations called Requests for Prototype Proposals (RPPs). The RPPs offer MCDC members the opportunity to propose prototype technologies to the technology requirements in each solicitation’s sub-objective area. Active and Forecasted solicitations are listed below, as are the status of RPPs for which submissions have been received.

If you are not a MCDC member and wish to become one, please click here for instructions.

RPP Release #
(Date)
RequirementRequiring OfficeSubmission TypeSubmission Due Date
RPP-19-08
(3/1/2019)
MCDC1908:Medical Countermeasure Prototype Development to Biological Toxins (PRE)DTRAWhite Paper
Full Proposal
4/1/2019 Noon ET
4/26/2019 Noon ET
RPP Release # (Date)RequirementRequiring OfficeSubmission StatusAwardeeAward DateEstimated Value
RPP-19-07
(1/31/2019)
19-07: Natural Product Chemical Medical CountermeasuresJPEO-CBRND
MCS
Received:
Selected:
Basket:
In Evaluation
RPP-19-06
(1/31/2019)
19-06: Novel and Innovative Prophylaxis/Pretreatment Medical Countermeasures (MCMs) to Protect the U.S. Warfighter Against Adverse Effects of Organophosphorus Nerve Agents (OPNAs)JPEO-CBRND
MCS
Received:
Selected:
Basket:
In Evaluation
RPP-19-05
(1/31/2019)
19-05 (TRE):
Prophylactic and Therapeutic cMCM Libraries, Mid to Late Pipeline Development
JPEO-CBRND
MCS
Received:
Selected:
Basket:
In Evaluation
RPP-19-04
(12/19/2018)
19-04 (PRE): Ebola Vaccine Prototype
JPM-MCS
Received:
Selected:
Basket:
In Evaluation
RPP-19-03
(11/1/2018)
19-04 (TRE): Development of Naloxone Auto-injectorJPEO-CBRND
MCS
Received:
Selected:
Basket:
In Evaluation
RPP-19-03
(11/1/2018)
19-03 (TRE): Development of Diazepam Auto-injectorJPEO-CBRND
MCS
Received: 6
Selected: 1
Basket: 3
In Negotiation
RPP-19-02
(12/4/2018)
19-02 (TRE/PRE): Development and Testing of a Rapid Response Antibody (Ab) Platform System and the Accelerated Development of a Safe and Efficacious Prototype Medical Countermeasure (MCM) Against a Biodefense Threat of InterestJPEO-CBRND
MCS
Received:
Selected:
Basket:
In Evaluation
RPP-19-01
(11/20/2018)
19-01 (TRE): Development of an FDA-Approved Smallpox Medical Countermeasure for a Post-Exposure Prophylaxis IndicationJPEO-CBRND
MCS
Received: 1
Selected: 1
Basket: 0
In Negotiation
RPP-18-09
(8/8/2018)
18-22 (PRE): Walter Reed Army Institute of Research Viral Disease Branch (WRAIR, VDB), Good Manufacturing Practices (GMP) Development of Dengue Purified Inactivated VaccinesJPEO-CBRND
JPM MCS
Received:
Selected:
Basket:
Requirement Canceled
RPP-18-06
(3/23/2018)
18-17 (PRE): Marburg Virus Vaccine DevelopmentDTRA
JSTO
Received: 3
Selected:
Basket: 3
RPP-18-06
(3/23/2018)
18-16 (TRE): Novel Therapeutics for Multidrug Resistant Bacterial Bio threat PathogensDTRA
JSTO
Received: 5
Selected: 1
Basket: 2
Battelle3/1/19$8,894,774
RPP-18-05
(4/12/2018)
18-19 (PRE): Development and utilization a monoclonal antibody platform prototype for development of monoclonal antibodies as medical countermeasures against threats of interest. Aerosolized Plague infection is the subject of this requirement.JPEO-CBRND
MCS
Received: 2
Selected: 1
Basket: 0
Ology Bioservices3/22/19$130,267,841
RPP-18-04
(4/5/2018)
18-15 (DET): Point-of-Care Diagnostics to identify the Causative Agents for Melioidosis and the PlagueDTRA
JSTO
Received: 3
Selected: 2
Basket: 0
Inbios International
Brimrose Technology Corp
8/27/18
9/24/18
$4,436,864
$1,319,680
RPP-18-04
(4/5/2018)
18-14 (PRE): Next Generation Devices for Delivery of Nucleic Acid VaccinesDTRA
JTSO
Received: 4
Selected: 0
Basket: 4
RPP-18-04
(4/5/2018)
18-13 (PRE): Prophylaxis / Pretreatment Against Francisella tularensisDTRA
JTSO
Received: 4
Selected: 0
Basket: 3
RPP-18-04
(4/5/2018)
18-12 (PRE): Francisella tularensis Immune AssaysDTRA
JTSO
Received: 3
Selected: 0
Basket: 3
RPP-18-04
(4/5/2018)
18-11 (PRE): Burkholderia Species Immune AssaysDTRA
JTSO
Received: 5
Selected: 0
Basket: 4
RPP-18-04
(4/5/2018)
18-10 (DET): Assay Development for the Identification of Markers of Venezuelan Equine Encephalitis Virus Infection in Animal ModelsDTRA
JTSO
Received: 2
Selected: 1
Basket: 1
In Negotiation
RPP-18-04
(4/5/2018)
18-09 (DET): Multiplex Vertical flow Paper-based Immunoassay (VPI) Diagnostic SystemDTRA
JTSO
Received: 2
Selected: 0
Basket: 1
RPP-18-03
(2/9/2018)
18-08 (TRE): Proof of Concept Formulations for CBRN Medical Countermeasures to be administered via AutoinjectorDTRA
JTSO
Received: 5
Selected: 2
Basket: 2
SRI International

Emergent BioSolutions
3/4/19

3/4/19
$1,940,766

$2,236,389
RPP-18-03
(2/9/2018)
18-07 (TRE): Discovery and Development of New Therapeutics to Treat Symptoms of Exposure to Organophosphorus Chemical Warfare Nerve AgentsDTRA
JSTO
Received: 1
Selected: 1
Basket: 0
Southwest Research Institute3/18/19$10,037,014
RPP-18-03
(2/9/2018)
18-06 (PRE): Enhanced circulatory stability and GMP manufacturing of phosphotriesterase (PTE) / organophosphorous hydrolase (OPH) variants as prophylaxis against a broad-spectrum of organophosphorus nerve agents (OPNAs)DTRA
JSTO
Received: 1
Selected: 1
Basket: 0
In Negotiation
RPP-18-02
(1/10/2018)
18-05 (TRE): Development of a Food and Drug Administration (FDA)-approved medical countermeasure (MCM) for treatment of multi-drug resistant bacterial biological warfare agents delivered via an aerosol route of exposureJPEO-CBRND
JPM MCS
Received: 1
Selected: 0
Basket: 1
RPP-18-02
(1/10/2018)
18-04 (TRE): Relevant Large Animal Model Prototypes for Organophosphorus (OP) Nerve Agent (NA) Intoxication and Therapeutic EvaluationsJPEO-CBRND
JPM MCS
Received: 2
Selected: 1
Basket: 1
SciTech Services9/12/18$235,797
RPP-18-01
(10/19/2017)
18-03 (TRE): Late Discovery and Development of Therapeutics to Treat Symptoms of Exposure to Organophosphorus Chemical Warfare Nerve AgentsDTRA
JSTO
Received: 1
Selected: 1
Basket: 0
Leidos8/16/18$10,966,574
RPP-18-01
(10/19/2017)
18-02 (DET): Development of Multiplex Molecular Diagnostics Based on CRISPR-Cas and other Synthetic Biology ApproachesDTRA
JSTO
Received: 0
Selected:
Basket:
RPP-18-01
(10/19/2017)
18-01 (DET): Rapid Single-molecule-based Diagnostic Platform Assessment of Pathogen Susceptibility to Anti-microbial AgentDTRA
JSTO
Received: 6
Selected: 2
Basket: 0
California Institute of Technology
General Electric
12/4/18

12/13/18
$3,387,096

$5,997,583
RPP-17-03
(6/17/2017)
17-08: Chemical Exposure In Vitro Diagnostics (ChemDx) JPEO-CBRND
JPM MCS
Received: 3
Selected: 2
Basket: 1
MRI Global10/10/18$9,653,670
RPP-17-03
(6/17/2017)
17-07: Man-Portable Diagnostics System (MPDS) – Expanded ScopeJPEO-CBRND
JPM MCS
Received: 4
Selected: 1
Basket: 1
Cepheid8/24/18$56,362,300
RPP-17-03
(6/17/2017)
17-06: Execution of Phase 1 Clinical Study for Venezuelan Equine Encephalitis (VEE) Monovalent Virus Replicon Particle (VRP) vaccineJPEO-CBRND
JPM MCS
Received: 4
Selected: 0
Basket: 2
No Award Made
RPP-17-02
(2/13/2017)
17-05: Man-Portable Diagnostics System (MPDS)JPEO-CBRND
JPM MCS
Received: 3
Selected: 1
Basket: 1
MRI Global9/1/17$36,364,633
RPP-17-02
(2/13/2017)
17-04: Development of Multi-Target Single-Vector Vaccine Prototype against aerosolized Venezuelan Equine Encephalitis Virus (VEEV)JPEO-CBRND
JPM MCS
Received: 1
Selected: 1
Basket: 0
Bavarian Nordic3/16/18$35,894,256
RPP-17-02
(2/13/2017)
17-03: Development of Marburgvirus (MARV) Vaccine Prototype against aerosolized MARVJPEO-CBRND
JPM MCS
Received: 2
Selected: 1
Basket: 1
Selectee did not execute Base Agreement
RPP-17-01
(1/13/2017)
17-02: Development of Efficacious Antiviral CountermeasuresJPEO-CBRND
JPM MCS
Received: 5
Selected: 0
Basket: 2
*Mapp BioPharmaceuticals11/7/17$40,831,616
RPP-17-01 (1/13/2017)17-01: Development of Monoclonal Antibody and Related Technologies as Medical Countermeasures against aerosolized Venezuelan Equine Encephalitis (VEE) VirusJPEO-CBRND
JPM MCS
Received: 3
Selected: 0
Basket: 2
No Award Made
RPP-16-02
(7/15/2016)
16-06: Eastern Equine Encephalitis Virus Advanced Technology Demonstration (EEEV ATD)JPEO-CBRND
JPM MCS
Received: 6
Selected: 0
Basket: 4
No Award Made
RPP-16-02
(7/15/2016)
16-05: Venezuelan equine encephalitis (VEE) Monovalent VLP Phase I Clinical StudyJPEO-CBRND
JPM MCS
Received: 2
Selected: 1
Basket: 1
SRI International2/3/17$4,922,193
RPP-16-02
(7/15/2016)
16-04: Lyophilized Formulation and Final Product Manufacturing Process for WEVEE VaccineJPEO-CBRND
JPM MCS
Received: 1
Selected: 0
Basket: 1
No Award Made
RPP-16-02
(7/15/2016)
16-03: Development of a Dual Drug Delivery Device (D4) AutoinjectorJPEO-CBRND
JPM MCS
Received: 5
Selected: 1
Basket: 2
Emergent BioSolutions7/25/17$23,145,596
RPP-16-01
(6/22/2016)
16-02: Development of Monoclonal Antibody Medical Countermeasures against Aerozolized Botulinum Toxin Serotypes A and BJPEO-CBRND
JPM MCS
Received: 1
Selected: 1
Basket: 0
Ology Bioservices9/30/16$39,820,156
RPP-16-01
(6/22/2016)
16-01: Fill/Finish of Venezuelan Equine Encephalitis (VEE) virus like particle (VLP) Bulk Drug ProductJPEO-CBRND
JPM MCS
Received: 3
Selected: 1
Basket: 1
SRI International12/8/16$660,715